Disease State Serum Samples for Biomarker and Diagnostic Research
Disease state serum provides a clotting-factor-free matrix that captures circulating antibodies, hormones, metabolites, cytokines, and other analytes reflecting active disease biology. Because serum is collected without anticoagulants and processed after complete clot formation, it offers distinct analytical advantages for immunoassays, autoantibody detection, hormone quantification, and clinical chemistry applications where clotting factors could interfere with downstream measurements. MT Group provides human disease state serum from carefully characterized patient populations across oncology, autoimmune, metabolic, and other therapeutic areas. Our prospective collection model means disease state serum samples are collected with the specific processing protocols, clinical annotation, and timepoint schedules your study requires—not retrofitted from an existing inventory.
Disease State Serum Samples for Biomarker and Diagnostic Research
Disease state serum provides a clotting-factor-free matrix that captures circulating antibodies, hormones, metabolites, cytokines, and other analytes reflecting active disease biology. Because serum is collected without anticoagulants and processed after complete clot formation, it offers distinct analytical advantages for immunoassays, autoantibody detection, hormone quantification, and clinical chemistry applications where clotting factors could interfere with downstream measurements. MT Group provides human disease state serum from carefully characterized patient populations across oncology, autoimmune, metabolic, and other therapeutic areas. Our prospective collection model means disease state serum samples are collected with the specific processing protocols, clinical annotation, and timepoint schedules your study requires—not retrofitted from an existing inventory.
Why Disease State Serum Requires a
Different Approach Than Healthy Donor Serum
Disease state serum for research demands more than a tube of blood and a diagnosis code. The research value of disease state serum samples depends on precise clinical context: What stage is the disease? What treatments has the patient received, and how have they responded? Are comorbidities present that could confound biomarker analysis? Is the sample from a pre-treatment baseline, an active therapy timepoint, or a post-progression draw?
MT Group designs disease state serum collections around these variables because they determine whether your specimens produce meaningful data or noise. Every collection begins with a detailed study design consultation where we define enrollment criteria, clinical data requirements, and processing specifications before a single tube is drawn. This is the same consultative approach that has driven over 90% subject retention in our longitudinal disease state serum studies and earned us the trust of pharmaceutical, biotechnology, and laboratory diagnostics companies since 2003.
Disease State Serum Collection Capabilities
MT Group collects disease state serum from diverse patient populations across our established site network. Below are the therapeutic areas we most commonly support, though our prospective collection model allows us to activate collections for conditions beyond those listed here.
Oncology
Disease state serum from cancer patients supports tumor marker research, immunotherapy biomarker studies, and diagnostic assay validation. Serum is the preferred matrix for many established oncology biomarkers including CA-125, CA 19-9, CEA, AFP, and PSA, as well as emerging protein-based and antibody-based analytes. We collect oncology serum across solid tumors including lung (NSCLC and SCLC), breast, colorectal, pancreatic (PDAC), hepatocellular carcinoma (HCC), ovarian, prostate, bladder, renal cell carcinoma, and glioblastoma (GBM), as well as hematologic malignancies. Collections can be stratified by treatment status (treatment naïve, on therapy, post progression), specific therapeutic regimens, and molecular subtypes when documented in the clinical record.
Autoimmune and Inflammatory Disease
Disease state serum from patients with autoimmune conditions is widely used for autoantibody detection (ANA, anti-dsDNA, ANCA, anti-CCP, RF), cytokine profiling, complement studies, and immunoglobulin quantification. Serum is the standard matrix for most clinical autoimmune diagnostic panels, making disease state serum essential for assay development and validation. Conditions include rheumatoid arthritis, systemic lupus erythematosus, psoriasis, atopic dermatitis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), multiple sclerosis, psoriatic arthritis, and other immune mediated disorders. Collections can be designed around disease activity scores (DAS-28, PASI, EASI, Mayo Score), treatment history including biologic naïve and biologic experienced populations, and washout status.
Metabolic Disease
Human disease state serum from patients with metabolic conditions including Type 1 and Type 2 diabetes, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD/NASH), thyroid disorders, dyslipidemia, and obesity. Serum is the preferred matrix for many endocrine and metabolic assays including thyroid function panels (TSH, T3, T4), insulin, C-peptide, and lipid profiles. These collections support clinical chemistry research, metabolomics studies, and biomarker validation for disease monitoring and therapeutic development. Clinical annotation commonly includes HbA1c levels, fasting glucose, lipid panels, BMI, and medication histories.
Neurological Conditions
Serum collections from patients with neurological and neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, mild cognitive impairment, multiple sclerosis, schizophrenia, bipolar disorder, generalized anxiety disorder, major depressive disorder, and neuropathic pain syndromes. Disease state serum for neurological research increasingly supports blood-based biomarker discovery, with applications in neurofilament light chain (NfL), phosphorylated tau, and other emerging circulating neuro-biomarkers.
Cardiovascular Disease
Disease state serum from patients with cardiovascular conditions including heart failure, atrial fibrillation, coronary artery disease, and post-myocardial infarction. Serum is the standard matrix for cardiac biomarkers including troponin, NT-proBNP, CK-MB, and myoglobin. Collections support cardiac biomarker research, lipid biomarker validation, and cardiovascular drug development programs.
Other Conditions
MT Group's prospective collection model is not limited to the categories above. We regularly activate disease state serum collections for respiratory conditions (COPD, asthma, IPF), renal disease, ophthalmologic conditions, rare diseases, and other therapeutic areas based on site feasibility and patient population access. Contact us to discuss your specific disease state serum requirements.
Disease State Serum
Processing Protocols
Serum processing differs fundamentally from plasma processing: blood is collected into tubes without anticoagulant, allowed to clot, and then centrifuged to separate the serum from the clot. The quality of disease state serum depends on proper clot formation, appropriate processing timing, and consistent centrifugation---variables that MT Group controls through detailed collection SOPs executed by experienced sites.
Collection Tube Options
Standard Serum Tubes (SST / Red-Top): Plain glass or plastic tubes without additives, used when no clot activator is desired. Blood is drawn and allowed to clot naturally at room temperature before centrifugation.
Serum Separator Tubes (SST / Gold-Top): Contain a clot activator and gel barrier that separates serum from the clot during centrifugation. SSTs are widely used for clinical chemistry and immunoassay applications and provide clean serum separation with reduced hemolysis risk.
Specialized Tubes: Tubes with specific additives or coatings may be used for particular research applications as specified in your study protocol.
Clot Formation and Processing Timing
Proper clot formation is critical to disease state serum quality. MT Group's collection SOPs specify clotting time (typically 30-60 minutes at room temperature), clotting conditions, and maximum time-to-centrifugation to ensure consistent specimen quality across all subjects. Processing timing is documented for every collection.
Aliquoting and Storage
Disease state serum is aliquoted according to your specifications---volume per aliquot, number of aliquots per subject, and tube type are all customizable. Specimens are stored at -20°C or -80°C depending on analyte stability requirements and shipped on dry ice to maintain the cold chain from collection site to your laboratory.
Clinical Annotation for
Disease State Serum
The research value of disease state serum samples depends as much on the clinical data accompanying them as on the specimens themselves. MT Group provides comprehensive, validated clinical annotation that goes well beyond a diagnosis and demographic summary.
Standard Clinical Data Elements
Every disease state serum collection includes demographics (age, sex, race/ethnicity, BMI), primary diagnosis with date of diagnosis, complete medical history and relevant comorbidities, current and prior treatment history with dates, dosing, and duration, concomitant medications, and lifestyle factors including smoking status and alcohol use. Additional standard laboratory values and clinical assessments collected as part of the patient's routine care are captured on customized case report forms.
Disease-Specific Annotation
Disease state serum for research often requires annotation tailored to the therapeutic area:
Oncology: Cancer stage and grade, tumor molecular subtype (when documented), prior lines of therapy, specific regimens and dates, progression dates, and surgical history.
Autoimmune: Disease activity scores (DAS-28, PASI, EASI, Mayo Score, CDAI), biologic treatment history, washout status, flare frequency, and duration of disease.
Metabolic: HbA1c, fasting glucose, lipid panels, BMI trends, insulin use, and oral medication history.
Treatment Response and Outcome Data
For prospective and longitudinal disease state serum collections, MT Group captures treatment response data when available through standard-of-care follow-up. This includes response classifications, progression events, treatment changes, and clinical outcomes. This longitudinal clinical context transforms disease state serum samples from isolated snapshots into connected datasets that support biomarker-outcome correlation studies.
Data Validation
MT Group's dedicated clinical data team reviews every case report form for completeness, internal consistency, and accuracy before specimens are released. Discrepancies between clinical data elements---such as a treatment history that conflicts with a stated diagnosis or timeline---are resolved directly with the clinical site. This validation step ensures that the clinical annotation accompanying your disease state serum is reliable and research-ready.
Longitudinal Disease State
Serum Collections
Tracking biomarker changes over time requires specimens collected at defined intervals from the same patients. MT Group has built its reputation on longitudinal disease state collections, achieving over 90% subject retention across multi-timepoint studies. This retention rate reflects strong site relationships, proactive subject management, and collection schedules designed around existing standard-of-care visit patterns to minimize patient burden.
Longitudinal disease state serum collections are particularly valuable for:
Treatment response monitoring: Pre-treatment baseline, on-therapy timepoints, and post-treatment follow-up to track serum biomarker dynamics across the treatment arc
Disease progression studies: Serial serum draws that capture evolving antibody profiles, tumor marker trends, and immune responses over months or years
Diagnostic assay validation: Serum panels from well-characterized patients at multiple disease stages to validate assay sensitivity and specificity across the disease spectrum
Vaccine and immunotherapy response: Tracking seroconversion, antibody titers, and immune responses at defined intervals following intervention
Matched Specimen Collections
Disease state serum can be collected alongside matched biospecimens from the same subjects and timepoints, including whole blood, plasma, buffy coat, urine, and---when the clinical setting permits---tissue biopsies. Matched serum-plasma collections from the same draw are particularly common, allowing researchers to compare analyte performance across both matrices.
Why Choose MT Group
for Disease State Serum
Consultative Study Design: MT Group does not simply accept orders for disease state serum samples. We ask detailed questions to fully understand your study objectives, analytical platforms, and clinical data requirements before designing a collection protocol. This upfront investment in study design prevents costly downstream problems caused by specimens that don't meet your actual research needs.
Realistic Feasibility Assessment: We conduct thorough site feasibility evaluations to provide honest projections about enrollment potential and timelines. We frequently take over disease state collections that other CROs have abandoned after overpromising and underdelivering, getting stalled studies back on track. By setting accurate expectations from the start, MT Group protects your research timelines and budget.
Proven Longitudinal Expertise: With over 90% subject retention rates in multi-timepoint studies, MT Group has demonstrated the operational discipline required for longitudinal disease state serum collections. Our project management team provides weekly study updates and detailed collection notifications that make accessioning straightforward for your laboratory team.
Rigorous Quality and Data Validation: Every disease state serum specimen undergoes quality review before release, including hemolysis assessment, volume verification, and labeling confirmation. Our clinical data team independently validates all annotation for completeness and internal consistency. If any specimen fails to meet agreed-upon specifications, we replace it at no additional cost.
Two Decades of Experience: MT Group has supported disease state serum collections for pharmaceutical, biotechnology, and diagnostics companies since 2003. This depth of experience means our sites understand the critical importance of following detailed collection protocols and our project teams know how to anticipate and resolve enrollment challenges before they impact your timelines.
Why Leading Researchers Choose MT Group
Frequently Asked Questions About Disease State Serum
What disease state serum samples are available?
MT Group provides disease state serum across oncology (lung, breast, colorectal, pancreatic, liver, ovarian, prostate, bladder, renal, GBM, and hematologic malignancies), autoimmune and inflammatory diseases (rheumatoid arthritis, lupus, psoriasis, IBD, multiple sclerosis), metabolic conditions (diabetes, NASH, metabolic syndrome), neurological conditions, cardiovascular disease, and other therapeutic areas. Our prospective collection model allows us to activate new disease state serum collections based on your specific requirements and site feasibility.
How are disease state serum specimens annotated?
Disease state serum specimens are accompanied by comprehensive clinical documentation including demographics, diagnosis with date, complete treatment history with regimens and response data, comorbidities, concomitant medications, lifestyle factors, and relevant laboratory values. Disease-specific annotation such as cancer staging, disease activity scores, antibody titers, or metabolic panels is captured on customized case report forms. All clinical data is validated by MT Group's dedicated data team for completeness and internal consistency before specimens are released.
When should I use serum instead of plasma for my research?
Serum is generally preferred for immunoassays, autoantibody detection, hormone measurements, tumor marker quantification, serological testing, and clinical chemistry applications where clotting factors could interfere with results. Plasma is typically preferred for coagulation studies, cfDNA and liquid biopsy applications, and certain proteomic analyses. Many biomarker studies collect matched serum and plasma from the same subjects to compare analyte performance across matrices. MT Group can help you determine the optimal matrix during study design consultation.
Can disease state serum be collected at multiple timepoints from the same patient?
Yes, longitudinal multi-timepoint collections are a core specialty. MT Group achieves over 90% subject retention in longitudinal disease state serum studies by designing collection schedules around standard-of-care visit patterns and maintaining strong site-subject relationships. Timepoints are defined during study design and can include pre-treatment baselines, on-therapy draws, post-treatment surveillance, and disease progression events.
How is disease state serum different from healthy donor serum?
Disease state serum reflects active pathology---elevated autoantibodies, altered immunoglobulin profiles, abnormal tumor markers, shifted hormone levels, and other analytes that are absent or present at different concentrations in healthy donors. Critically, the clinical annotation requirements are substantially different: disease state serum for research requires detailed treatment histories, disease staging, response data, and comorbidity profiles that healthy donor serum does not. MT Group's disease-specific case report forms capture this clinical context to ensure your specimens support meaningful translational research.
Can disease state serum be matched with other specimen types?
Yes, disease state serum is routinely collected alongside matched whole blood, plasma, buffy coat, and urine from the same subjects and timepoints. Matched serum-plasma pairs from the same blood draw are especially common for matrix comparison studies. When the clinical setting permits, matched tissue biopsies can also be collected.
What is the turnaround time for disease state serum collections?
Prospective disease state serum collections typically begin 2-4 weeks after receiving a purchase order. During this period, MT Group develops a collection SOP, assembles study-specific material kits, and onboards collection sites. Nearly all collections fit under established umbrella IRB protocols, eliminating the need for additional approvals. Enrollment timelines depend on your specific eligibility criteria and disease population.
Contact MT Group
Complete the form below to discuss your tissue requirements with our experts.
No obligation consultation. Response within one business day.
